Oral follicle-stimulating hormone receptor agonist affects granulosa cells differently than recombinant human FSH.

Objective: To determine whether TOP5300, a novel oral follicle-stimulating hormone (FSH) receptor (FSHR) allosteric agonist, elicits a different cellular response than recombinant human FSH (rh-FSH) in human granulosa cells from patients undergoing in vitro fertilization.
Design: Basic science research with a preclinical allosteric FSHR agonist.
Setting: University hospital.
Patient(s): Patients with infertility at a single academic fertility clinic were recruited under an Institutional Review Board-approved protocol. Primary granulosa cell cultures were established for 41 patients, of whom 8 had normal ovarian reserve (NOR), 17 were of advanced reproductive age (ARA), 12 had a diagnosis of polycystic ovary syndrome (PCOS), and 4 had a combination of diagnoses, such as ARA and PCOS.
Intervention(s): Primary granulosa-lutein (GL) cell cultures were treated with rh-FSH, TOP5300, or vehicle.
Main Outcome Measure(s): Estradiol (E ₂ ) production using enzyme-linked immunosorbent assay, steroid pathway gene expression of StAR and aromatase using quantitative polymerase chain reaction, and FSHR membrane localization using immunofluorescence were measured in human GL cells.
Result(s): TOP5300 consistently stimulated E ₂ production among patients with NOR, ARA, and PCOS. Recombinant FSH was the more potent ligand in GL cells from patients with NOR but was ineffective in cells from patients with ARA or PCOS. The lowest level of FSHR plasma membrane localization was seen in patients with ARA, although FSHR localization was more abundant in cells from patients with PCOS; the highest levels were present in cells from patients with NOR. The localization of FSHR was not affected by TOP5300 relative to rh-FSH in any patient group. TOP5300 stimulated greater expression of StAR and CYP19A1 across cells from all patients with NOR, ARA, and PCOS combined, although rh-FSH was unable to stimulate StAR and aromatase (CYP19A1) expression in cells from patients with PCOS. TOP5300-induced expression of StAR and CYP19A1 mRNA among patients with ARA and NOR was consistently lower than that observed in cells from patients with PCOS.
Conclusion(s): TOP5300 appears to stimulate E ₂ production and steroidogenic gene expression from GL cells more than rh-FSH in PCOS, relative to patients with ARA and NOR. It does not appear that localization of FSHR at cell membranes is a limiting step for TOP5300 or rh-FSH stimulation of steroidogenic gene expression and E ₂ production.
Competing Interests: Declaration of interests J.Z.G. reports funding from NIH R01 HD032067 and Baylor College of Medicine Department of Obstetrics and Gynecology for the submitted work. D.M. has nothing to disclose. H.Y. is the Chief executive officer and reports stock options from CanWell Pharma. F.S.S. has nothing to disclose. H.L.J. has nothing to disclose. W.E.G. has nothing to disclose. M.M.M. has nothing to disclose. S.P. has nothing to disclose.
(Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)